Hepln-13

• Description:

  Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer[1].

• Product Name Alternative:

  Clodantoin, Xenazoic acid; CV58913

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hepln-13.html

• Purity:

  99.34

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  BrC1=CC=C(C=C1)C(N2)NC3=C4C2=CC=CC4=CC=C3

• Molecular Formula:

  C17H13BrN2

• Molecular Weight:

  325.20

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5 (5) :1352-1362.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [64369-13-7]